Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 EUR | -4.00% |
|
-9.19% | +5.99% |
May. 30 | Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 30 | Transcript : Nanoform Finland Oyj, Q1 2024 Earnings Call, May 30, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
139.2 USD | +3.34% | +3.29% | 14.71B | ||
1.68 EUR | -4.00% | -9.19% | 162M | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.99% | 162M | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants